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1050-42 Roper fue ion  Therapy  With E i ther  Intravenous 
Thrombolya la  or  P r imary  PTCA In E lder ly  Pat ients  Is 
Beneficial: One-Year Results From a Nationwide French 
Registry of Acute Myocardial Infarction 
Nicolas Dsnchtn, Laurent Vaur, Nathalie Genes, Jean Ferrieres, Michael Angioi, Sylvia 
Etienne, Jean-Pierre Cambou, the USIK investigators, HEGP 20 rue Leblanc, Paris, 
France. 
Background: The role of early reperfusion therapy at the acute stage of MI in elderly 
patients is debated, Aim and Methods: The aim of this study was to analyze the prognos- 
tic role of reperfusion with IV thrombolysis or pdmary PTCA in the nationwide USIK data- 
base, which prospectively included all pts admitted to a CCU for an AMI in France in 
November 1995. For the purpose of the present study, only patients admitted within 24 
hours of AMI and with one-year follow-up available were included. Results: Of the 1,838 
patients included, 785 were • 70 years old, of whom 225 (29 %) had early reperfusion 
therapy with thrombolysis (n=173) or primary PTCA (n=52). Patients treated with early 
reperfusion had a baseline profile that differed from that of patients treated convention- 
ally: women (31% vs 50 %, p < 0,001), admission within 6 hours of symptom onset (84 
% vs 54 %, p < 0.001), history of systemic hypertension (48 % vs 60 % p < 0,002), history 
of stroke (5 % vs 11%, p < 0.01), peripheral artedal disease (8 % vs 18 %, p < 0.001); 
congestive heart failure (5 % vs 20 %, p < 0.001), previous MI (12 % vs 25 %, p < 0,001 ), 
anterior location of current MI (40 % vs 28 %, p < 0,002). Overall one-year Kaplan-Meier 
survival was 78 % for patients with versus 64 % for those without reperfusion therapy (p 
< 0.01). Cox multivariate analysis showed that reperfusion therapy was an independent 
predictor of survival (RR 0.71; 95% CI: 0.50-0,99), along with age (RR: 1.04, 95% Ch 
1.02-1,07), anterior location of MI (RR: 2.14, 95 % Cl: 1.64-2,80), history of stroke (RR: 
1.81, 95 % CI: 1,25-2.61), and history of congestive heart failure (RR: 1,66, 95 % CI: 
1.18-2.32). When the analysis was repeated after exclusion of the patients who under- 
went primary PTCA, treatment with IV thrombolysis was also associated with higher one- 
year survival, and thrombolysis was of borderline statistical significance in the Cox multi- 
variate analysis (RR: 0.72, 95 % CI: 0.50-1.04, p=0.08). Conclusions: data from this large 
"real life" registry indicate that reperfusion therapy with either thrombolysis or primary 
PTCA is associated with improved one-yeer survival in patients over 70 years of age. 
1050-43 Gender Is an Independent Predictor of Both In-Hospital 
and One-Year Outcomes Following Pr imary  In tervent ion  
for Acute Myocardial In farct ion 
Kimbarlv A. Skeldino. Kishore Harjai, Laxmi Mehta, Gregg W. Stone, David A, Cox, 
Judith A, Boura, Lorelei L Grines, William W. O'Neill, Cindy L Grines, William Beaumont 
Hospital, Royal Oak, Michigan. 
Background: Prior studies have indicated that female gender contributes to worse prog- 
nosis from acute myocardial infarction (MI), elective percutaneous intervention (PCI), 
and coronary artery bypass grafting (CABG). However the impact of gender on outcomes 
following primary angioplasty for acute MI is not well established. 
Methods: We evaluated the outcomes of 3401 patients from the PAMI studies receiving 
primary intervention for acute MI, of whom 27% were female. Clinical data, angiographic 
details and outcomes were evaluated. 
Results: Females were older (66¢12 vs 59+12, p=0.00Ol ), more often diabetic (22% vs 
14%, p--O.001), and hypertensive (57% vs 42%, p=0.001). They more often had prior 
congestive heart failure (3,4% vs 1.9%, p=O.009), and cerebrovascular events (9% vs 
4%, p=0.001). Females were less often current smokers (36% vs 44%, p=0.001), had 
less incidence of prior CABG (2.6% vs 4.7%, p=0.010), prior Mi (12% vs 15%, p=0,020), 
and prior PCI (7.7% vs 10.3%, p=0,021), Angiographically, patients were similar: initial % 
stanosis (98+6 vs 98+5, p=0.180), ejection fraction (48+12 vs 49+12, p=0,594), final % 
stenosis (15+17 vs 15¢17, p=0.881) and TIMI flow pre (p=0.108) and post (p=0.747) pro- 
cedure. Females had less muitivessel disease (44% vs 49%, p=0,006). Females had 
higher in hospital death (4.6% vs 2.3%, p=0.001), death at 1 year (10% vs 6%, p=0.001) 
and target vessel revascularization (TVR) at 1 year (18% vs 13%, p=O.005). Adjusted for 
baseline differences, females remained at higher risk of in-hospital cardiovascular events 
including TVR, disabling stroke, reinfarction or death following primary PCI (8.7% vs 
5.7%, p--0.001). This difference continues at 1 year (27% vs 19%, p=0,001). On multi- 
variate analysis female gender is an independent predictor for in-hospital events 
(p=0.0025, OR=1.634, 95% C1=1.189-2.247) and remains predictive at 1 year 
(p=<0.0001, OR=1.553, 95%CI 1.258-1.916), 
Conclusions: This data suggests that female gender is a significant independent predic- 
tor of major cardiovascular events at one year following primary PCI for acute MI. Further 
study is needed to determine if additional clinical and/or angiographic conditions also 
contribute to this difference. 
1050-44 Outcomes for Asian Indians Following Acute ST 
E levat ion Myocardial Infarction: Results From the  
GUSTO Trials 
Vanu Menon. Lilin She, Rabia Arshad, Anne S. Hellkamp, Sunil V. Rao, Judith S. 
Hochman, E Magnus Ohman, St Lukes Rooseveit, NY, New York. 
Background: Relative outcomes following thrombolytic therapy for Asian Indians (AI) 
compared to Caucasians (C) have not been reported. Methods: We compared clinical 
Outcomes in 475 AI enrolled in GUSTO-I (1990-3) GUSTO lib (1993-5) and GUSTO-Ill 
(1995-7) and compared them to 54799 C. Results: AI were significantly younger, shorter 
and Jightar than C (all P< 0.001 ). They were more likely to be male, have a history of dia- 
betes but were less likely to be current smokers ( all P < 0.001). Time to treatment, pre- 
senting heart rate, rates of hypertension and hypercholestarolemia were similar (all p = 
NS). Despite lower rates of angiography (37% vs 53%, p = 0.0001) and diminished left 
ventricular function in AI (47.7 ± 14.2 vs 51.5 ± 13.2, p = 0.004), distribution of 1-2-3 ves- 
sel disease were similar. Although rates of moderate/severe bleeding were comparable, 
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AI had less strokes (0.21 vs 1.47%, p = 0.04). Overall 30 day and 1 year mortality for AI 
(6.99 vs 8.00% and 11.04% vs 11.36%) were similar as were rates of reinfarction and 
shock. Thirty day (OR 1.399, 95% C[ 0.878, 2.230, p= 0.16) and 1 year mortality (OR 
1.144, 95% CI 0.770, 1.699, p = 0.51) for AI remained similar to C after adjusting for age, 
gender, weight, height, systolic BP, Killip Class, heart rate, diabetes, hypertension, infarct 
location, smoking status, time to treatment, rates of previous MI, prior CABG, prior stroke 
and angina, as well as US location of enrollment. Amongst countries enrolling a large 
number of AI, observed 30 day mortality rates for AI in Canada (n = 200), USA (n = 108) 
and South Africa (n = 79) were 7.5%, 5.6% and 13.9% respectively. Conclusion: 30 day 
and 1 year mortality for AI are similar to C following acute ST elevation MI. Regional dif- 
ferences in outcome deserve further exploration. 
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1051-27 Predict ing and Preventing Myocardial In farct ion  With 
C lop idogre l  in Pat ients  With Symptomatic 
Atherothromboais: Results From CAPRIE 
Christopher P. Cannon. on behalf of the CAPRIE Investigators, Brigham and Women's 
Hospital, Boston, Massachusetts. 
Background: Prevention of myocardial infarction (MI) is a major goal of therapy in 
patients (Pts) with documented atherothrombosis. Identification of Pts at higher dsk of 
developing a subsequent MI may assist in selecting more aggressive therapy for these 
Pts to prevent of MI. Although prediction rules now exist for mortality, few prediction rules 
exist for ML Also, factors that predict mortality (usually related to left ventricular failure) 
may not be the same as predictors of ML Methods: In the CAPRIE trial 19,185 Pts with 
recent prior MI, stroke or documented peripheral arterial disease were randomized to 
receive clopidogrel or aspidn (ASA), We used multivariate (MV) analysis to develop a risk 
score for MI. Results: A new MI occurred in 5,04% of Pts treated with ASA vs. 4,20% for 
clopidogrel, a 19.2% relative reduction, p=0,008. MV predictors of MI were: Prior MI 
(p<0.0001), prior angina (p<O.0001), prior peripheral arterial disease (p<0.0001), highest 
quartile of creatinine (p<0,0001), diabetes (p=0.013), age _> 65 years (p=0.015), prior 
stroke (p=0.0497) and treatment with clopidogrel (O.R. = 0.80, adjusted p=0.0067). 
When stratifying by number of risk factors, the benefit of clopidogrel was an absoJute 
1,3% reduction in MI in Pts with 1-2 risk factors, and 5.2% in Pts with 5 or more risk fac- 
tors.(Figure) Conclusions: Risk of MI can be predicted across a 4 fold range, from 4 to 
17% over 3 years. Benefit of clopidogrel was seen in both low and high risk subgroups, 
supporting its use in a wide spectrum of patients. 
MI Risk at 3 years based on # Risk 





£ e | 
1 2 3 4 5+ 
Number of Risk Factors 
1051-28 Ramipril Prevents Major Cardiovascular Events in High- 
Risk Women: Results of  the  HOPE Trial 
Eva Lonn, Rosa Roccaforte, Qilong Yi, Jacqueline Bosch, Jeffrey Probsffield, Peter 
Steight, GiUes Dagenais, Salim Yusuf, McMaster Universi~ Hamilton, Ontario, Canada. 
Background: it has been suggested based on subgroup analyses in heart failure (HF) 
and/or post myocardial infarction (MI) trials, that ACE inhibitors may be less effective in 
women than in men. These studies have generally included few women and were thus 
not adequately powered to assess the effects of ACE inhibitors in women. Furthermore, 
there are no data in women without HF and with preserved left ventdcular ejection frac- 
tion (LVEF). 
Methods: In the Heart Outcome Prevention Evaluation (HOPE) trial we enrolled a large 
number of women, who were at least 55 years of age and had documented vascular dis- 
ease or diabetes and additional risk factor(s)without HF and with preserved LVEF. 
Patients were randomized to ramipri110rag/day or placebo and mean follow up was 4.5 
years. Treatment effects in women were eva)uatad as a preplanned subgroup analysis. 
Results: There were 2,480 women. At baseline the placebo and ramipril groups were well 
balanced. Mean age was 66.5 years, 1,642 (66%) women had a history of CAD, 929 
(37%) had prior MI, 273 (11%) had pdor stroke or TIA, 1322 (53%) had diabetes and 
1496 (60%) hypertension. Treatment with ramipril resulted in a significant reduction in the 
primary outcome, the composite of MI, stroke and CV death and in other Outcomes of 
interest (Table). There was no difference (lack of statistical heterogeneity) in the magni- 
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tude of the effect of ramipril in women vs. men. 
Conclusions: ACE inhibition with ramipril is highly effective in high-risk women without HF 
and with preserved LVEF. 
Effect of Ramlprll In Women 
Placebo (n=1201) Ramipril (n=1279 RR (95% CI) p 
MI, stroke, CV death 179 (14.9%) 145 (11.3%) 0.76 (0.61-0.94) 0.01 
MI 113 (9.4%) 105 (8.2%) 0.87 (0.67-1.14) 0.3 
Stroke 58 (4.8%) 40 (3.1%) 0.61 (0.43-0.86) 0.004 
CV Death 139 (11.6%) 118 (9.2%) 0.79 (0.62-1.02) 0.06 
Revascularizations 173 (14.4%) 150 (11.7%) 0.81 (0.65-1.00) 0.05 
Heart Failure 136 (11.3%) 117 (9.2%) 0.81 (0.63-1.03) 0.08 
Worsening Angina 312 (26.0%) 275 (21.5%) 0.80 (0.68-0.94) 0.007 
New Diabetes 27 (4.7%) 16 (2.7%) 0.58 (0.31-1.08) 0.08 
1051-29 Effects of Vitamin E on Cardiovascular and 
Microvascular Outcomes in High-Risk Diabetic Patients 
Eva Lonn. Hertzel Gerstein, Janice Pogue, Qilong Yi, Byron J. Hoogwerf, Jacqueline 
Bosch, GUles Dagenais, Salim Yusuf, McMaster Universi~ Hamilton, Ontario, Canada. 
Background: Oxidative stress is an important mechanism of atherogenesis and 
microvascular damage in diabetes. Elevated protein kinase C (PKC) may also increase 
microvascular damage. Vitamin E is an antioxidant and decreases PKC activation. 
Methods: We evaluated natural source Vitamin E (RRR-alpha-tocopheryl acetate) 400 
IU/day vs. placebo in 3,654 high-risk persons with diabetes enrolled in the randomized 
controlled Heart Outcomes Prevention Evaluation (HOPE) trial. Median follow-up was 
4.5 years. Data on major clinical outcomes were collected. Glycated hemoglobin (HbAlc) 
and serum creatinine were measured at baseline and yearly thereafter. Urinary albumin 
excretion was measured at baseline, 1 year and study end. Participants with albumin/ 
creatinine ratio higher than 36 mg/mmol had 24 hour urine collections. Nephropathy was 
defined as 24-hour urinary albumin excretion of 300 mg or more or total protein excretion 
of 500 mg or more. 
Results: Baseline characteristics were well balanced. Patients' mean age was 65 years, 
3,572 had type 2 diabetes, 1,356 were women, 2,189 had known CAD, 244 had prior 
stroke, 678 peripheral arterial disease, 2,031 hypertension, 2,384 hypercholesterolemia. 
Major event rates (in %) were similar in the 2 groups (Table). Serial measurements of 
HbAlc, urinary albumin/creatinine ratio and serum creatinine were also similar in the 2 
groups. 
Conclusions: Vitamin E 400 IU/day has a neutral effect on CV outcomes and microvas- 
cular complications in high-risk diabetics, 
CV and Mlcrovasculsr Event Rates (in %) 
Placebo (n=1816) Vitamin E (n=1838) RR (95% CI) 
MI, Stroke and CV Death 17.2 17.7 1.03 (0.88-1.21) 
MI 11.5 11.5 1.01 (0.83-1.22) 
Stroke 4.6 5.6 1.21 (0.91-1.62) 
CV Death 8.0 7.7 0.97 (0.77-1.23) 
Total mortality 12.8 11.9 0.93 (0.77-1.12) 
Heart failure 4.2 4.6 1.11 (0.81-1.51) 
Revascularizations 15.3 15.2 0.99 (0.82-1.17) 
Overt Nephropathy 7.2 7.9 1.12 (0.88-1.44) 
New Microalbuminuria 37.5 35.3 0.91 (0.79-1.03) 
Retinal Laser Therapy 10.0 9.9 0.99 (0.81-1.22) 
1051-30 Pharmacodynamic Interactions Between Tadalafil and 
Nitrates 
Robert Kloner. Jeff Emmick, Alun Bedding, Dennis Humen, Eli Lilly and Company, Erl 
Wood Manor, United Kingdom. 
Background: Tadalafil is a selective PDE5 inhibitor under regulatory review for the treat- 
ment of erectile dysfunction. Because sildenafil, another PDE5 inhibitor, is contraindi- 
cated in men taking nitrates, studies were undertaken to examine potential interactions 
between tadalafil and nitrates. Methods: Two double-blind, randomized, 3-way cross- 
over studies were conducted in patients with stable angina to determine: 1) Study A - 
response to sublingual nitroglycerin (SL NG) administered 2 hours after tadalafil 5 or 10 
m 9 or placebo (n=51); and 2) Study B - response after tadalafil 5 or 10 mg or placebo 
administered during daily long-acting nitroglycerin (LA NG) therapy (n=45). Reeulls: The 
table shows the results for the primary endpoint, which was mean maximal change in 
standing systolic BP (MMCSBP). 
Comparative Analysis of Standing MMCSBP Between Treatment Groups (mmHg) 
Tadalafil (10 mg)-Placebo Tadalafil (5 mg)-Placebo 
Mean Lower Bound of Mean Lower Bound of 
Difference 95% CI Difference 95% CI 
Study A (SL NG) -3 -6 -8* -12 
Study B (LA NG) -2 -6 0 -4 
*Mean difference statistically significant based on non-inferiority analysis 
Numbers of Patients with Standing SBP <85 mmHg (outliers) 
Placebo Tadalafil 5 mg Tadalafi110 m 9 
Study A (SL NG) 1 13 11 
Study B (LA NG) 0 0 6 
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There were no statistically significant differences in either study between tadalafil 5 or 10 
mg and placebo in the sitting position. Conclusions: Tadalafil had minimal effects, rela- 
tive to placebo, on mean blood pressure changes induced by either SL NG or LANG. 
However, the frequency of outliers was higher in the tadalafil treatment groups, indicating 
that in a subset of patients, tadalafil augments the decrease in BP induced by nitrates. 
These results suggest that, as with sildenafil, tadalafil should not be used in combination 
with nitrates. 
1051-45 Randomized Comparison of Exercise Training Versus 
PTCA/Stent in Stable Coronary Artery Disease: Effects 
on Clinical Status and Maximal Exercise Capacity 
Katrin Conradi, Sven M6bius-Winkler, Claudia Walther, Peter Sick, Jiangtao Yu, Kai 
Kenziorra, Regine Kluge, Rainer Hambrecht, Gerhard Schuler, University of Leipzig, 
Heart-Center, Department of Cardiology, Leipzig, Germany, University of Leipzig, 
Department of Nuclear Medicine, Leipzig, Germany. 
Introduction: In patients (pts) with stable coronary artery disease (CAD) regular exercise 
training has the therapeutic potential to improve physical work capacity (PWC). The aim 
of the present study was to evaluate the effects of exercise training in comparison to an 
interventional approach (PTCA and stent implantation) in pts with symptomatic CAD with 
respect to symptom-free PWC. 
Methods: 100 male pts with stable CAD (amenable for PTCA/stent implantation) were 
prospectively randomized to either a training (T, n=50) or an intervention group (INT, 
n=50). Pts of the training group exercised 20 minutes daily on a bicycle ergometer 
whereas pts in the intervention group received initially a PTCNstent implantation. At the 
beginning and after 6 months patients underwent a maximal symptom limited exercise 
stress test to assess PWC and maximal oxygen uptake (VO2 max). 
Results: After 6 months pts of both groups demonstrated a significant improvement in 
clinical status from 1.33±0.13 to 0.6±0.11 (CCS-class, p<0.01 vs. begin) in T and 
1.65±0.11 to 1.02±0.12 (p<0.01 vs. begin) in INT, respectively. Regular exercise training 
was associated with a significant increase in PWC (132=4.1 to 161±5 Watt; p<0.05 vs, 
INT) and peak oxygen uptake ( 22.2±0.6 to 25.3±0.9 mL./kgxmin, p<0.05 vs. INT) in T, 
whereas INT showed no difference (119=3,4 to 124±4 Watt, n.s.; 20.8±0.6 to 
21.5=0.7mL/kgxmin, n.s.) Twenty-six pts of T and fifteen of INT were completely free of 
clinical symptoms after 6 months 
Conclusions: These data suggest that in a selected daily physical exercise training 
seems to be a feasible alternative to an interventional approach with respect to clinical 
status and functional work capacity. 
1051-46 Assessment of Reperfusion Therapy on Regional and 
Global Left Ventricular Function in Patients With 
Chronic Total Coronary Artery Occlusions 
Cenaiz Ermis. AdU Boz, Venkat Tholakanahalli, Selim Yalcinkaya, Ender Semiz, Oktay 
Sancaktar, Leslie W. Miller, Necmi Deger, David G. Benditt, Cardiovascular Division, 
University of Minnesota, Minneapolis, Minnesota, Cardiovascular Division, University of 
Akdeniz, Antalya, Turkey. 
Background: The regional and global ventricular function benefit achieved by percutane- 
ous coronary intervention (PCI) with repertusion of the artery supplying the infarct area in 
acute myocardial infarction (AMI) is well described. In addition, several trials indicate that 
PCt in AMI, reduces morbidity and mortality. Conversely, although the survival benefit of 
PCI in the setting of chronic total coronary occlusion (CTO) has recently been shown to 
be of little value, little is known of the potential effects on regional and global left ventricu- 
lar function after late recanalization of CTO. This prospective study examined whether 
PCI improves regional and global left ventricular function (LVF) in CTO. 
Methods: Patients (pts) having at least one coronary artery occluded for >6 weeks dura- 
tion, were included in the study. Exercise TI-201 myocardial perfusion scintigraphy 
(TMS), multiple gated acquisition (MUGA) ventriculography, and 2-dimensional echocar- 
diography (Echo) were performed in each pt to assess both regional and global LVF 
before and 6 weeks after PCI. Paired sample t-tests were utilized for statistical analysis. 
Results: Thirty-five pts were enrolled in the study. Fifteen pts were subsequently 
excluded because of inability to open the artery and one because of emergent angio- 
plasty. In the remaining 19 pts (16 male and 3 female, mean age of 58=5 years) ejection 
fraction (EF) pre and post PCI, was 51±7% and 58±6% using Simpson's method 
(p<0.001) by Echo, and it was 45=1% and 53=1% (p<0.01) by MUGA, respectively. 
Echocardiographic wall motion score was 24±9 before and 15±6 (p<0.001) after PCI. 
Exercise perfusion score (21±1 and 14±1 [p=0.01]), rest perfusion score (15±1 and 12±1 
[p=0.02]), and re-injection perfusion score (14=1 and 11=1 [p =0.07]) all also improved. 
Conclusion: Percutaneous coronary reperfusion therapy significantly improved the 
regional and global left ventricular function in patients with chronic total coronary occlu- 
sion. Thus, although PCI may not benefit survival in CTO pts, improvement in ventricular 
function may provide important symptom benefits. 
1051-47 Nitric Oxide Activity in Complex Atheromatous Plaques 
Dimitris Tousoulis. Costas Tentolouris, Tom Crake, Costas Toutouzas, Athansios Trikas, 
Christos Pitsavos, Christodoulos Stetanadis, Graham Davies, Pavlos Toutouzas, 
Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, 
Greece, Cardiology Unit, Hammersmith Hospital, London, United Kingdom. 
Background: Administration of L-arginine (LA) may stimulate the release of nitric oxide 
and improve myocardial ischemia.We sought to examine the effects of LA administration 
on coronary stenosis vasomotion in patients with coronary artery disease (CAD). 
Methods: Intracoronary infusions o1 normal saline, the receptor mediated nitric oxide 
stimulant LA (50 and 150 I~mol/min) and nitroglycerin (GNT) (250 mcg bolus) were 
administered in 15 patients with CAD and stable angina. Coronary stenoses were classi- 
fied as smooth (smooth with regular borders) or complicated (irregular borders). The 
